

Printability of pharmaceutical Fused Deposition Modeling (FDM) feedstock material: Mechanical characterisation of FDM filaments and the FDM 3D printing process

Elke Prasad, John Robertson, Gavin W. Halbert

EPSRC Future Manufacturing Research Hub in Continuous Manufacturing and Advanced Crystallisation, University of Strathclyde, 99 George Street, Glasgow, G1 1RD, UK

CONTACT INFORMATION: elke.prasad@strath.ac.uk.



PURPOSE

3D printing (3DP) of pharmaceutical formulations via commercially available FDM printers facilitates advanced control of the microstructure of the tablet core and therefore drug release properties. For this 3DP process an intermediate feedstock material is manufactured and used in the FDM process.

However, mechanical and rheological properties of pharmaceutically approved polymers are often not suitable for this process. In order to identify suitable filaments for the FDM process, the objective of this study was to perform a mechanical and rheological characterisation of the feedstock material during an FDM process.

OBJECTIVE(S)

To assess the printability of FDM feedstock material by mechanically characterising the filaments and the extrusion during an FDM 3DP process.

METHOD(S)

- Hot-Melt-Extrusion (HME): 5-50 % (w/w) Paracetamol (PCM) in Affinisol 15LV™ were extruded on a 16 mm Hot-Melt-Extruder [1]
- Mechanical characterisation of filaments was performed on a TA-XT Plus Texture Analyser
- Mechanical characterisation of the extrusion process of FDM filaments were recorded on a Texture Analyser TA-XT (Figure 1): ABS (MAXX), PLA (MAXX) and 5-50% w/w PCM-Affinisol 15LV™ filaments
- Complex viscosity was measured on a Haake Mars III rotational rheometer

RESULT(S)

Mechanical testing




Figure 2: Compression test to determine maximum force on filament during feeding. Maximum force (N) for commercial (ABS, PLA) and in-house produced (5-50% w/w PCM-Affinisol™ 15LV) filaments.




Figure 3: Compression test: Mechanical assessment of filaments using a texture analyser TA-XT equipped with mini grippers.

Summary

	Maximum Force Extrusion, 0.2mm nozzle, 4.8mm ³ /s (N)	Maximum Force Extrusion, 0.4mm nozzle, 4.8mm ³ /s (N)	Maximum Force Compression test (N)	Complex viscosity (η*, Pas) at 190°C	Printability ¹ Yes (Y) No (N)
5PCOM	no extrusion	11.8 ± 0.9	12.8 ± 3.0	4142	Y
10PCOM	11.5 ± 1.2	9.0 ± 3.2	10.2 ± 1.8	3309	Y
20PCOM	7.2 ± 0.5	7.4 ± 0.7	2.2 ± 0.5	1623	Y
25PCOM	3.4 ± 0.3	3.5 ± 0.3	0.7 ± 0.1	not measured	Y
30PCOM	no extrusion	no extrusion	2.0 ± 0.5	1011	N
35PCOM	no extrusion	no extrusion	0.7 ± 0.1	not measured	N
40PCOM	no extrusion	3.0 ± 0.2	10.8 ± 2.4	554.9	N
45PCOM	4.4 ± 3.3	2.4 ± 0.6	15.3 ± 4.2	not measured	Y
50PCOM	6.4 ± 1.3	2.2 ± 0.3	10.6 ± 2.2	249.1	Y

Table 1: Summary of experimental results.

FUNDING / GRANTS / ENCORE / REFERENCE OR OTHER USE

The authors would like to acknowledge that this work was carried out in the CMAC National Facility supported by the EPSRC (Grant ref EP/P006965/1) and by UKRPIF (UK Research Partnership Fund) award from the Higher Education Funding Council for England (HEFCE) (Grant ref HH13054). G. W. Halbert is funded by Cancer Research UK (C149/A20496). We would like to thank the National Facility team for their support in this project. We would also like to thank Dow Chemicals for the donation of Affinisol™ 15LV polymer.

Reference: 1. Prasad E, Islam MT, Goodwin DJ, Megarry AJ, Halbert GW, Florence AJ, Robertson J 2019. Development of a hot-melt extrusion (HME) process to produce drug loaded Affinisol™ 15LV filaments for fused filament fabrication (FFF) 3D printing. Additive Manufacturing 29:100776.

Maximum force during extrusion – 0.2 mm nozzle diameter




Figure 4: Maximum force recorded during extrusion of commercial filaments (ABS @240 °C, PLA @190 °C) and in-house prepared filaments (5-50% w/w PCM-Affinisol 15LV™ @190 °C) through an FDM print head [1] equipped with a 0.2mm round nozzle diameter. Extrusion was performed at volumetric speeds of 1.2 (blue), 2.4 (orange), 3.6 (grey) and 4.8 mm³/s (yellow).

Maximum force during extrusion – 0.4 mm nozzle diameter




Figure 5: Maximum force recorded during extrusion of commercial filaments (ABS @240 °C, PLA @190 °C) and in-house prepared filaments (5-50% w/w PCM-Affinisol 15LV™ @190 °C) through an FDM print head [1] equipped with a 0.4mm round nozzle diameter. Extrusion was performed at volumetric speeds of 1.2 (blue), 2.4 (orange), 3.6 (grey) and 4.8 mm³/s (yellow).

Maximum force during extrusion – 0.8 mm nozzle diameter




Figure 6: Maximum force recorded during extrusion of commercial filaments (ABS @240 °C, PLA @190 °C) and in-house prepared filaments (5-50% w/w PCM-Affinisol 15LV™ @190 °C) through an FDM print head [1] equipped with a 0.8mm round nozzle diameter. Extrusion was performed at volumetric speeds of 1.2 (blue), 2.4 (orange), 3.6 (grey) and 4.8 mm³/s (yellow).

Maximum force during extrusion – 1.0 mm nozzle diameter




Figure 7: Maximum force recorded during extrusion of commercial filaments (ABS @240 °C, PLA @190 °C) and in-house prepared filaments (5-50% w/w PCM-Affinisol 15LV™ @190 °C) through an FDM print head [1] equipped with a 1.0mm round nozzle diameter. Extrusion was performed at volumetric speeds of 1.2 (blue), 2.4 (orange), 3.6 (grey) and 4.8 mm³/s (yellow).

CONCLUSION(S)

Mechanical properties of an FDM process for commercial and in-house prepared pharmaceutically relevant feed stock material were investigated and have shown the material dependant impact of print geometries and print speed on the FDM process; informing future development of pharmaceutically relevant feedstock material.




Figure 1: Custom mount for FDM print head in texture analyser.